Your session is about to expire
← Back to Search
BCX7353 for Hereditary Angioedema (APeX-S Trial)
APeX-S Trial Summary
This trial is testing a drug to see if it can prevent angioedema attacks in people with HAE.
- Hereditary Angioedema
- Prophylaxis
APeX-S Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAPeX-S Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 & 3 trial • 387 Patients • NCT03472040APeX-S Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the most similar treatments to BCX7353 that have been studied in the past?
"BCX7353 was first studied in 2018 at Study Center. Since that time, there have been 6 completed studies with 3 more presently active. A significant number of these studies originate from Marietta, Georgia."
Are there any available openings for people who want to participate in this clinical trial?
"The clinical trial was posted on 2018-02-16 and was last edited on 2020-12-15, which indicates that the study is no longer recruiting participants. Although this trial is not seeking candidates anymore, there are 32 other studies presently accepting participants right now."
Where is this research being conducted?
"Right now, 42 hospitals and medical facilities are enrolling patients for this clinical trial. While the sites in Marietta, Hershey and Indianapolis are the closest to the original research locations, participating sites are located across the country to make enrolling more convenient for patients."
Has this research been done before?
"BCX7353 clinical trials began in 2018 with the first study being completed that same year. 121 patients were involved in the initial Phase 1 trial sponsored by BioCryst Pharmaceuticals. The success of this first trial led to the approval of BCX7353 as a Phase 3 drug. Presently, there are 3 active trials involving BCX7353 taking place in 51 different cities and 23 unique countries."
Share this study with friends
Copy Link
Messenger